噻托溴铵、布地奈德/福莫特罗及其联合治疗对D组稳定期慢性阻塞性肺疾病患者C反应蛋白水平的影响  

The Effects of Tiotropium and/or Budesonide/Formoterol on C-reactive Protein Levels in Stable Chronic Obstructive Pulmonary Disease Patients of Group D

作　　者：姜天香 程德云[2] 史永红[3] 林益华[3] 

机构地区：[1]厦门大学附属第一医院心内科,福建厦门361003 [2]四川大学华西医院呼吸内科,四川成都610041 [3]厦门大学附属第一医院呼吸内科,福建厦门361003

出　　处：《中国卫生标准管理》2016年第20期122-124,共3页China Health Standard Management

摘　　要：目的探讨噻托溴铵(Tio)、布地奈德/福莫特罗(Bud/Form)及其联合治疗对D组稳定期慢性阻塞性肺疾病患者C反应蛋白(CRP)水平的影响。方法 D组稳定期慢性阻塞性肺疾病患者,随机分为Tio组、Bud/Form组以及联合治疗组,比较治疗前后患者外周血CRP水平。结果 Tio组受试者治疗前后外周血CRP水平变化无差异。Bud/Form组及联合治疗组受试者治疗后外周血CRP水平下降。结论与单用Tio相比,Bud/Form单用或者联用Tio能够一定程度地降低D组稳定期慢性阻塞性肺疾病患者的CRP水平。Objective To investigate the effects of tiotropium（Tio）and/or budesonide/formoterol（Bud/Form） on C-reactive protein（CRP）levels in COPD patients of group D. Methods Stable COPD patients were randomized into three groups to receive inhaled therapy,Tio,Bud/Form,Tio＋Bud/Form. CRP concentrations were measured before randomization and during the treatment. Results Group Tio ：there was no differences of CRP levels between the baseline and during the treatment. Group Bud/Form and Group Tio＋Bud/Form ：CRP levels declined after treatment. Conclusion Compared with Tio,Bud/Form alone or in combination with Tio reduced CRP levels in stable COPD patients of group D.

关 键 词：慢性阻塞性肺疾病 C反应蛋白 噻托溴铵 布地奈德 福莫特罗 

分 类 号：R563[医药卫生—呼吸系统]